ArticleClinical and translational radiation oncology2026
Radiotherapy for the management of bone metastases in differentiated thyroid cancer.
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Purpose: Bone metastases are observed in over 50% of patients with differentiated thyroid cancer (DTC) who develop metastatic disease. Local treatments including external beam radiation therapy (RT) may be used for radioactive iodine-refractory, progressive, or symptomatic disease. The purpose of this study was to evaluate the efficacy of radiotherapy doses and techniques for DTC bone metastases. Materials and Methods: This retrospective study included all patients with DTC who received RT for bone metastases. The primary outcome was treated metastasis control (TMC), calculated from the date of radiotherapy completion to the date of lesion progression, death, or last follow-up. The biological effective dose (BED, α/β = 10) was used to compare radiotherapy regimens. The dose-response relationship was evaluated using BED Results: In total, 107 patients with DTC were treated for 280 bone metastases between 2003 and 2023. Patients were stratified into two groups: high BED Conclusion: In this retrospective cohort study conducted at the Princess Margaret Cancer Center, a clear dose-response relationship was identified for patients with DTC bone metastases. When suitable, treatment of these patients should include a higher dose exceeding BED
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.